Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

3DTUMOUR

Financiado

Cerrado

Development of a high throughput microplate based device to analyse the patient...

Development of a high throughput microplate based device to analyse the patient derived tumour microenvironment Cancer and tumours are exceptionally heterogeneous in tissue and cellular composition, clinical stage, and mutational status. Additionally, the presence of multiple cancers or metastatic tumours in patients leads to complicated dr... ver más

31/07/2025

ASOC CENTRO DE INV...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

ASOC CENTRO DE INVESTIGACION COOP EN BIO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 3-4 | 6M€

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-10-26

ERC-2023-POC: ERC PROOF OF CONCEPT GRANTS Objective:Objectives:The ERC Proof of Concept Grants aim at facilitating exploration of the commerci...

I+D

Cerrada hace 2 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

ASOC CENTRO DE INVESTIGACION...

150.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CROC Unravelling ChemoResistance mechanisms and improving first-l... 215K€ Cerrado

MicroC Agent Based Modelling of Gene Networks to model clonal selec... 2M€ Cerrado

RESISTANCEPROGRAMS Tumor recurrence and therapeutic resistance: exploring and e... 2M€ Cerrado

ANGIOTOX Histopathologic and Mechanistic Assessment of Angiogenesis I... 2M€ Cerrado

OVADEX Defining the role of the tumor microenvironment in treatment... Cerrado

OPTATIO OPtimizing TArgets and Therapeutics In high risk and refract... 4M€ Cerrado

Duración del proyecto: 21 meses Fecha Inicio: 2023-10-26
Fecha Fin: 2025-07-31

Líder del proyecto

ASOC CENTRO DE INVESTIGACION COOP EN BIO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 3-4 | 6M€

Presupuesto del proyecto 150K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cancer and tumours are exceptionally heterogeneous in tissue and cellular composition, clinical stage, and mutational status. Additionally, the presence of multiple cancers or metastatic tumours in patients leads to complicated drug regimens resulting in high off-target toxicity, unexpected drug resistance and difficulties in understanding the therapeutic effects. Despite a global investment in oncological drug development reaching 5 bn USD, less than 5% of all oncological drugs in the pipeline enter the therapy toolbox. Given the huge burden that cancer poses at all levels in society - leading cause of mortality worldwide, expected to reach 20 M deaths by 2050- technologies that enable pharmaceutical companies to increase the efficiency of drug development may alleviate the threat imposed to the more than 50 M people currently living with cancer. Such technologies include pre-clinical models that represent the tumour microenvironment and reveal the effect of drug candidates in laboratory tumour replicas. To provide clinically relevant information, such models must be patient specific and represent simultaneously the specificity of the target tissue and the cell heterogeneity of the tumour microenvironment. In addition, to be industrially relevant, they must be implementable, reproducible and high throughput. Commercially available solutions do not meet these requirements. 3DTUMOUR provides a proprietary technology to produce multiple 3D bioprinted replicas of patient-derived tumour models that faithfully represent the therapeutic target for a drug candidate. 3DTUMOUR aims at increasing the drug development success rate by transferring to industry this pharmaceutical testing platform. The successful outcome of this PoC will provide clinicians with a tool to test the efficacy of drugs ex vivo, accelerating the onset of efficient treatments and reducing off-target toxicity and unexpected drug resistance by applying a personalized-medicine approach.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores